COPENHAGEN (Reuters) – Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk, on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.
The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings’ largest individual investment in antimicrobial resistance therapies to date, it said in a statement.
Novo Holdings, which controls 76% of the votes in Denmark’s Novo Nordisk last week announced a major investment in a new energy transition fund, as it is looking to expand its portfolio beyond health.
(Reporting by Louise Breusch Rasmussen, editing by Jane Merriman)
